Open AccessAssociation of Treatment With Losartan vs Candesartan and Mortality Among Patients With Heart Failure
Author(s) -
Henrik Svanström,
Björn Pasternak,
Anders Hviid
Publication year - 2012
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2012.452
Subject(s) - candesartan , medicine , losartan , heart failure , hazard ratio , proportional hazards model , confounding , cardiology , cohort study , angiotensin ii , confidence interval , blood pressure
The benefit of angiotensin II-receptor blockers (ARBs) in heart failure is thought to be a class effect, but no head-to-head randomized trials have compared individual ARBs. Results from observational studies suggest that losartan may be associated with increased mortality in patients with heart failure compared with other ARBs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom